Gross Adam's Insider Trades & SAST Disclosures
Gross Adam's most recent trade in Adma Biologics Inc was a trade of 15,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gross Adam.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2025 | 15,000 | 840,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.46 per share. | 15 Apr 2025 | 15,000 | 2,061,850 (2%) | 0% | 21.5 | 321,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 15 Apr 2025 | 15,000 | 2,076,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.46 per share. | 15 Apr 2025 | 6,000 | 2,055,850 (2%) | 0% | 21.5 | 128,760 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 4.88 per share. | 10 Apr 2025 | 2,817 | 283,878 | - | 4.9 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 19 Mar 2025 | 15,000 | 2,082,850 (2%) | 0% | 5.4 | 81,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2025 | 15,000 | 855,950 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 19 Mar 2025 | 15,000 | 2,067,850 (2%) | 0% | 18.9 | 283,800 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 19 Mar 2025 | 6,000 | 2,061,850 (2%) | 0% | 18.9 | 113,520 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.91 per share. | 06 Mar 2025 | 56,438 | 2,097,363 (2%) | 0% | 16.9 | 954,367 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.02 per share. | 06 Mar 2025 | 29,513 | 2,067,850 (2%) | 0% | 17.0 | 502,311 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.78 per share. | 25 Feb 2025 | 54,867 | 2,153,801 (2%) | 0% | 15.8 | 865,801 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.44 per share. | 25 Feb 2025 | 18,018 | 2,208,668 (2%) | 0% | 15.4 | 278,198 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 376,744 | 376,744 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 252,022 | 2,226,686 (2%) | 0% | 0 | Common Stock | |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 6.26 per share. | 16 Jan 2025 | 2,196 | 281,061 | - | 6.3 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.15 per share. | 31 Dec 2024 | 14,343 | 1,974,664 (2%) | 0% | 17.1 | 245,982 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.10 per share. | 22 Nov 2024 | 48,967 | 1,989,007 (2%) | 0% | 21.1 | 1,033,204 | Common Stock |
| Vimeo Inc | Gross Adam | Director | Grant, award, or other acquisition of securities at price $ 4.89 per share. | 10 Oct 2024 | 2,811 | 278,864 | - | 4.9 | 13,750 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.99 per share. | 30 Sep 2024 | 21,752 | 2,037,974 (2%) | 0% | 20.0 | 434,822 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.35 per share. | 01 Sep 2024 | 6,194 | 276,052 | - | 5.4 | 33,138 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.29 per share. | 26 Aug 2024 | 389,356 | 2,059,726 (2%) | 0% | 17.3 | 6,732,900 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 341,960 | 741,020 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 26 Aug 2024 | 341,960 | 2,401,686 (2%) | 0% | 3.4 | 1,145,566 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.69 per share. | 26 Aug 2024 | 236,889 | 2,059,726 (2%) | 0% | 17.7 | 4,191,088 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 26 Aug 2024 | 64,405 | 2,124,131 (2%) | 0% | 3.4 | 215,757 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 64,405 | 1,082,980 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 60,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.80 per share. | 26 Aug 2024 | 60,000 | 2,296,615 (2%) | 0% | 10.8 | 648,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 55,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Aug 2024 | 55,000 | 2,179,131 (2%) | 0% | 5 | 275,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 47,396 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.91 per share. | 26 Aug 2024 | 47,396 | 2,449,082 (2%) | 0% | 2.9 | 138,159 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 40,500 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.37 per share. | 26 Aug 2024 | 40,500 | 2,236,615 (2%) | 0% | 9.4 | 379,485 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 16,984 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.96 per share. | 26 Aug 2024 | 16,984 | 2,196,115 (2%) | 0% | 6.0 | 101,225 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Purchase of securities on an exchange or from another person at price $ 5.01 per share. | 12 Aug 2024 | 50,000 | 282,246 | - | 5.0 | 250,400 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.81 per share. | 01 Aug 2024 | 6,194 | 232,246 | - | 3.8 | 23,599 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 3.63 per share. | 18 Jul 2024 | 3,186 | 238,440 | - | 3.6 | 11,566 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.83 per share. | 01 Jul 2024 | 6,194 | 235,254 | - | 3.8 | 23,723 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.18 per share. | 30 Jun 2024 | 21,752 | 2,059,726 (2%) | 0% | 11.2 | 243,187 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 44,444 | 241,448 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Other type of transaction at price $ 3.21 per share. | 14 Jun 2024 | 460,000 | 2,191,475 (2%) | 0% | 3.2 | 1,476,600 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Sale of securities on an exchange or to another person at price $ 10.72 per share. | 14 Jun 2024 | 100,000 | 2,081,475 (2%) | 0% | 10.7 | 1,071,980 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jun 2024 | 10,000 | 2,181,475 (2%) | 0% | 0 | Common Stock | |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 01 Jun 2024 | 6,194 | 197,004 | - | 3.9 | 24,033 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 01 May 2024 | 6,194 | 203,198 | - | 3.6 | 22,484 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.00 per share. | 01 Apr 2024 | 4,361 | 209,392 | - | 4 | 17,444 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President,CEO, and Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.60 per share. | 31 Mar 2024 | 21,752 | 2,651,475 (3%) | 0% | 6.6 | 143,563 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 06 Mar 2024 | 55,003 | 2,701,990 (3%) | 0% | 6.1 | 336,618 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.16 per share. | 06 Mar 2024 | 28,763 | 2,673,227 (3%) | 0% | 6.2 | 177,180 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.01 per share. | 01 Mar 2024 | 4,361 | 213,753 | - | 5.0 | 21,849 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.36 per share. | 29 Feb 2024 | 9,588 | 2,756,993 (3%) | 0% | 5.4 | 51,392 | Common Stock |
| Adma Biologics Inc | S. Adam Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 870,950 | 870,950 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Grossman S. Adam | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 557,728 | 2,766,581 (3%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Grossman S. Adam | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.26 per share. | 25 Feb 2024 | 22,457 | 2,208,853 (2%) | 0% | 5.3 | 118,124 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.97 per share. | 01 Feb 2024 | 5,008 | 218,114 | - | 4.0 | 19,882 | Common Stock |
| Vimeo Inc | Gross Adam | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.92 per share. | 01 Jan 2024 | 5,008 | 223,122 | - | 3.9 | 19,631 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.52 per share. | 31 Dec 2023 | 23,057 | 2,231,310 (2%) | 0% | 4.5 | 104,218 | Common Stock |
| Vimeo Inc | Adam Gross | Director, Interim CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 01 Dec 2023 | 4,226 | 228,130 | - | 3.7 | 15,636 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.61 per share. | 15 Aug 2023 | 1,589,987 | 2,523,088 (2%) | 1% | 4.6 | 7,329,840 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 583,224 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. | 15 Aug 2023 | 583,224 | 4,623,544 (5%) | 0% | 3.7 | 2,134,600 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.54 per share. | 15 Aug 2023 | 510,469 | 4,113,075 (4%) | 0% | 4.5 | 2,318,959 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 400,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 15 Aug 2023 | 400,000 | 3,690,320 (4%) | 0% | 3.2 | 1,288,000 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 350,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.71 per share. | 15 Aug 2023 | 350,000 | 4,040,320 (4%) | 0% | 3.7 | 1,298,500 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 277,604 | 47,396 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.92 per share. | 15 Aug 2023 | 277,604 | 3,290,320 (3%) | 0% | 2.9 | 809,216 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.35 per share. | 15 Aug 2023 | 277,131 | 3,012,716 (3%) | 0% | 2.4 | 651,258 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 277,131 | 181,569 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 212,500 | 387,500 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share. | 15 Aug 2023 | 212,500 | 2,735,585 (3%) | 0% | 1.7 | 354,875 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.33 per share. | 15 Aug 2023 | 3 | 2,523,085 (2%) | 0% | 4.3 | 13 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2023 | 3,826 | 92,564 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.69 per share. | 30 Jun 2023 | 20,051 | 2,523,085 (2%) | 0% | 3.7 | 73,988 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 44,444 | 88,738 | - | - | Common Stock | |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2023 | 4,213 | 44,294 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.31 per share. | 31 Mar 2023 | 17,853 | 2,543,139 (2%) | 0% | 3.3 | 59,093 | Common Stock |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 17.48 per share. | 14 Mar 2023 | 2,295 | 13,084 (0%) | 0% | 17.5 | 40,117 | Class A Common Stock |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 4,685 | 15,961 (0%) | 0% | 0 | Class A Common Stock | |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 4,685 | 11,276 (0%) | 0% | 0 | Class A Common Stock | |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.49 per share. | 01 Mar 2023 | 582 | 15,379 (0%) | 0% | 18.5 | 10,761 | Class A Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 1,147,385 | 1,147,385 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 573,695 | 2,584,599 (2%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 25 Feb 2023 | 23,607 | 2,560,992 (2%) | 0% | 3.4 | 80,264 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 25 Feb 2023 | 14,412 | 2,018,411 (2%) | 0% | 3.4 | 49,289 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 25 Feb 2023 | 7,507 | 2,010,904 (2%) | 0% | 3.6 | 26,650 | Common Stock |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 25 Feb 2023 | 4,018 | 2,032,823 (2%) | 0% | 3.4 | 13,742 | Common Stock |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,764 | 7,191 (0%) | 0% | 0 | Class A Common Stock | |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 23 Feb 2023 | 600 | 6,591 (0%) | 0% | 0 | Class A Common Stock | |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 3,906 | 40,080 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.87 per share. | 04 Jan 2023 | 166,867 | 2,036,841 (2%) | 0% | 3.9 | 645,775 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2022 | 3,886 | 36,174 | - | - | Common Stock | |
| Adma Biologics Inc | Adam S. Grossman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.43 per share. | 30 Sep 2022 | 101,315 | 2,188,725 (2%) | 0% | 2.4 | 246,195 | Common Stock |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2022 | 2,508 | 32,288 | - | - | Common Stock | |
| Vimeo Inc | Adam Gross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 24,035 | 29,780 | - | - | Common Stock | |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 2,611 | 5,300 (0%) | 0% | 0 | Class A Common Stock | |
| RE/MAX Holdings Inc - Ordi... | Adam Grosshans | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 127 | 5,427 (0%) | 0% | 0 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges